su011248
Mucosal Lentiginous Melanoma
Dana-Farber Cancer InstitutePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Mucosal Lentiginous Melanoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Nilotinib Institute of Cancer Research, United Kingdom | Phase 2 | B |
Same molecule, other indications
su011248 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →